levofloxacin has been researched along with lopinavir in 5 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (lopinavir) | Trials (lopinavir) | Recent Studies (post-2010) (lopinavir) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 2,383 | 499 | 1,358 |
| Protein | Taxonomy | levofloxacin (IC50) | lopinavir (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.7 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.12 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.035 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.5114 | |
| Protease | Human immunodeficiency virus 1 | 0.025 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.6 | |
| Protease | Human immunodeficiency virus 1 | 0.0175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N | 1 |
| Abdulai, SI; Adewole, KE; Asogwa, NT; Ishola, AA; Tijjani, H | 1 |
1 review(s) available for levofloxacin and lopinavir
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
4 other study(ies) available for levofloxacin and lopinavir
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin | 2020 |
Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Coronavirus Nucleocapsid Proteins; COVID-19 Drug Treatment; Esterases; Hemagglutinins; Humans; Hydroxychloroquine; Levofloxacin; Ligands; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; SARS-CoV-2 | 2022 |